Dr. David Canes, MD

Dr. Canes practices at Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health.

Dr. Canes' NPI, 1841246576, was assigned on May 25, 2006. Dr. Canes graduated from Weill Cornell Medicine in 2001. Dr. Canes holds Massachusetts license 219272.

Dr. Canes' primary practice is Lahey Clinic, at 41 & 45 Mall Road, Burlington, MA 01803 in Middlesex County. The practice phone is (781) 744-5100.

Dr. Canes' primary practice is Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health. Dr. Canes is also affiliated with Beverly Hospital. The medical group on file is Lahey Clinic. Dmand AI also links Dr. Canes to 3 more hospitals and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Canes practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Canes' primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Canes is board certified in urology by the American Board of Urology. Dmand AI has Dr. Canes' licenses on file in 4 states: Massachusetts, New Hampshire, Florida and Ohio.

Dmand AI lists bladder disease, bladder removal, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery and kidney stone disease among the conditions Dr. Canes treats.

CMS data shows 1,047 Medicare services from Dr. Canes across 13 procedure codes in 2024, for 448 Medicare patients. Medicare paid $85,880 for them.

CMS counts 448 Medicare patients who saw Dr. Canes in 2024. The largest group is 65 to 74, with 243 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 5% are also on Medicaid. Their average risk score is 1.18, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Canes' median patient age at 72, with 16% women.

In 2024, Dr. Canes wrote 248 Medicare Part D claims for 83 patients. 98% of them were for generic drugs. CMS names the drug for 203 of them, across 4 drugs with 11 or more claims each, at $2,858 in total drug cost. In 2023, CMS named 217 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Canes for performance year 2024, reported through an alternative payment model (APM). Dr. Canes accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Canes as offering telehealth. CMS counts 42 procedures of prostate resection by Dr. Canes, more than 96% of the clinicians it reports for that procedure.

Dmand AI links 43 papers to Dr. Canes, published from 2008 to 2024. 2021 was the busiest year, with 4. The most frequent topics are Laparoscopy, Prostatectomy and Prostatic Neoplasms. Dr. Canes has published most often in Urology. Dr. Canes' most frequent co-authors are Alireza Moinzadeh, MD, Brendan Browne and George J. Chiang, MD.

Dmand AI links Dr. Canes to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Urinary Bladder Neoplasms and Urinary Bladder Diseases.

CMS Open Payments shows 30 general payments to Dr. Canes from 16 drug and device companies from 2018 to 2025. Speaker and faculty fees make up the largest share, 86% of the total. Progenics Pharmaceuticals, Inc. paid the most, $4,619.

Dr. Canes graduated from Weill Cornell Medicine in 2001.

Dr. Canes is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.